T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (58)	8/27/1998 6:52:00 PM
From: scaram(o)uche	Read Replies (1) of 1073

Everyone is qualified to comment. We may laugh, but biotech investors need to get used to people laughing at them. :-) "Under the terms of the licensing agreement with Warner-Lambert, Unigene is eligible to receive up to an additional $46.5 million in milestone payments, of which $13.5 million would be received prior to the initiation of Phase I studies." They only have about one quarter of burn left, and they just recently got the first 2 of the 13.5. Nonetheless, UGNE looks really interesting. The price:book means that it just doesn't qualify for T/FIF. The $4-8 million private placement really takes them outside of the scope of this thread..... we're looking for companies that have stable financials, or where somewhat unstable financials have led to "book, but good science" status. Yeah, I was wading in and buying today too. Gluttons.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next